

Amendments to the Claims:

Please cancel claims 28, 39-42, and 45-48 without prejudice.

Please amend claims 20, 30, 35, 43, and 44 as follows:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. – 19. (Cancelled)

20. (Currently amended) A method for diagnosing colon cancer comprising detecting ~~evidence of~~ differential expression of PPP3CC in a patient colon sample, wherein ~~evidence of~~ differential expression is detected by measuring the level of an expression product of PPP3CC; said expression product ~~at least 98% identical to~~ having the nucleotide sequence of SEQ ID NO:1587; wherein an increase in the level of the expression product in the sample of at least 50% relative to a non-cancerous control is indicative of colon cancer ~~and wherein the expression product encodes a polypeptide with protein phosphatase activity.~~

21. – 29. (Cancelled)

30. (Currently amended) The method of claim 20 wherein the non-cancerous control is a ~~known normal~~ tissue of the same tissue type as in the patient sample.

31. (Cancelled)

32. (Previously presented) The method of claim 20 wherein the level of the expression product in the sample is increased at least 100% relative to the control.

33. **(Previously presented)** The method of claim 20 wherein the level of the expression product in the sample is increased at least 150% relative to the control.

34. **(Cancelled)**

35. **(Currently amended)** A method of diagnosing lymphoma, colon cancer, or stomach cancer ~~or breast cancer~~ comprising:

a) determining the expression level of ~~an expression product~~ a nucleic acid comprising ~~[[a]] the~~ nucleotide sequence of SEQ ID NO:1587, ~~or a full complement thereof~~, in a patient sample; and

b) comparing said level of the ~~expression product~~ nucleic acid in (a) to a level of the ~~expression product~~ nucleic acid in a second sample, said second sample comprising a ~~normal~~ non-cancerous tissue, wherein a difference between the level of the ~~expression products~~ nucleic acid in (a) and the level of the ~~expression products~~ nucleic acid in the second sample indicates that the patient has lymphoma, colon cancer, or stomach cancer ~~or breast cancer~~.

36. – 42. **(Cancelled)**

43. **(Currently amended)** A method for diagnosing colon cancer comprising comparing levels of PPP3CC protein in a patient colon sample to that of a non-cancerous colon control sample, wherein the PPP3CC protein is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO:1587, wherein an increase in the level of PPP3CC protein in the patient colon sample of at least 50% relative to ~~[[a]]~~ said non-cancerous colon control is indicative of colon cancer.

44. **(Currently amended)** A method for diagnosing colon cancer comprising comparing levels of a polypeptide encoded for by a nucleic acid comprising a nucleotide sequence at least 98% identical to SEQ ID NO:1587 in a patient colon sample to a non-cancerous colon control sample, wherein an increase in the level of the polypeptide in the patient colon sample of at least

50% relative to [[a]] said non-cancerous colon control is indicative of colon cancer, said polypeptide having protein phosphatase activity.

45. – 48. **(Cancelled)**